Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells

Blood

Volumn 106, Issue 7, 2005, Pages 2287-2294

  Heinzerling, Lucie ^b   Künzi, Valerie ^b   Oberholzer, Patrick A ^b   Kündig, Thomas ^b   Naim, Hussein ^b   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD150 ANTIGEN; ETRETIN; GAMMA INTERFERON; LIVE VACCINE; MEASLES ANTIBODY; MEASLES VACCINE; MEMBRANE COFACTOR PROTEIN; MESSENGER RNA; METHOTREXATE; ONCOLYTIC VIRUS; PEGINTERFERON; STEROID; VIRUS NUCLEOPROTEIN;

ADULT; AGED; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DIZZINESS; ERYTHEMA; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INJECTION SITE REACTION; MALE; MEASLES VIRUS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PUVA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; STAINING; TUMOR CELL; UNPLEASANT SENSATION;

EID: 27144511701     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2004-11-4558     Document Type: Article

References (44)

1. Dummer R, Kempf W, Hess Schmid M, Haffner A, Burg G. Therapy of cutaneous lymphoma: current practice and future developments. Onkologie. 2003;26:366-372.
2. Kaye FJ, Bunn PJ, Steinberg SM, et al. A randomized trial comparing combination electronbeam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321:1784-1790.
3. Asadullah K, Docke WD, Haeussler A, Sterry W, Volk HD. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol. 1996;107:833-837.
4. Dummer R, Heald PW, Nestle FO, et al. Sézary syndrome's T-cell clones display T helper 2 cytokines and express the accessory factor-1 (interferon γ receptor β chain). Blood. 1996;88:1383-1389.
5. Sun WH, Pabon C, Alsayed Y, et al. Interferon-α resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood. 1998;91:570-576.
6. Willers J, Haffner A, Zepter K, et al. The interferon inhibiting cytokine IK is overexpressed in cutaneous T cell lymphoma derived tumor cells that fail to upregulate major histocompatibility complex class II upon interferon-gamma stimulation. J Invest Dermatol. 2001;116:874-879.
7. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6:821-825.
8. Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF. Regression of Hodgkin's disease after measles [letter]. Lancet. 1981;1:1112.
9. Mota HC. Infantile Hodgkin's disease: remission after measles. Br Med J. 1973;2:421
10. Zygiert Z. Hodgkin's disease: remissions after measles. Lancet. 1971;1:593.
11. Ziegler JL. Spontaneous remission in Burkitt's lymphoma. Natl Cancer Inst Monogr. 1976;44:61-65.
12. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet. 1971;2:105-106.
13. Grote D, Russell SJ, Cornu TI, et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood. 2001;97:3746-3754.
14. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood. 2001;98:2002-2007.
15. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med. 2002;8:527-531.
16. Phuong LK, Allen C, Peng KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 2003;63:2462-2469.
17. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004;64:4919-4926.
18. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol. 2000;81:2341-2364.
19. Naniche D, Yeh A, Eto D, Manchester M, Friedman RM, Oldstone MB. Evasion of host defenses by measles virus: wild-type measles virus infection interferes with induction of Alpha/Beta interferon production. J Virol. 2000;74:7478-7484.
20. Ogata S, Ogata A, Schneider-Schaulies S, Schneider-Schaulies J. Expression of the interferon-alpha/beta-inducible MxA protein in brain lesions of subacute sclerosing panencephalitis. J Neurol Sci. 2004;223:113-119.
21. Fah J, Pavlovic J, Burg G. Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem. 1995;43:47-52.
22. Kaltoft K, Bisballe S, Rasmussen HF, Thestrup PK, Thomsen K, Sterry W. A continuous T-cell line from a patient with Sezary syndrome. Arch Dermatol Res. 1987;279:293-298.
23. Kaltoft K, Bisballe S, Dyrberg T, Boel E, Rasmussen PB, Thestrup PK. Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol. 1992;28A(3 Pt 1):161-167.
24. Heinzerling L, Burg G, Dummer R, et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther. 2005;16:35-48.
25. Panelli MC, Wang E, Monsurro V, Marincola FM. The role of quantitative PCR for the immune monitoring of cancer patients. Expert Opin Biol Ther. 2002;2:557-564.
26. Dummer R, Nestle F, Wiede J, et al. Coincidence of increased soluble interleukin-2 receptors, diminished natural killer cell activity and progressive disease in cutaneous T-cell lymphomas. Eur J Dermatol. 1991;1:135-138.
27. Dummer R, Döbbeling U, Geertsen R, Willers J, Burg G, Pavlovic J. Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication. Blood. 2001;97:523-527.
28. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood. 2004;103:1641-1646.
29. Peng KW, Frenzke M, Myers R, et al. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum Gene Ther. 2003;14:1565-1577.
30. Jurianz K, Ziegler S, Garcia-Schuler H, et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol. 1999;36:929-939.
31. Ono N, Tatsuo H, Hidaka Y, Aoki T, Minagawa H, Yanagi Y. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol. 2001;75:4399-4401.
32. Erlenhofer C, Duprex WP, Rima BK, ter Meulen V, Schneider-Schaulies J. Analysis of receptor (CD46, CD150) usage by measles virus. J Gen Virol. 2002;83:1431-1436.
33. McQuaid S, Cosby SL. An immunohistochemical study of the distribution of the measles virus receptors, CD46 and SLAM, in normal human tissues and subacute sclerosing panencephalitis. Lab Invest. 2002;82:403-409.
34. Ehrengruber MU, Ehler E, Billeter MA, Naim HY. Measles virus spreads in rat hippocampal neurons by cell-to-cell contact and in a polarized fashion. J Virol. 2002;76:5720-5728.
35. Esolen LM, Park SW, Hardwick JM, Griffin DE. Apoptosis as a cause of death in measles virusinfected cells. J Virol. 1995;69:3955-3958.
36. Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002;20:2251-2266.
37. Bell JC, Lichty B, Stojdl D. Getting oncolytic virus therapies off the ground. Cancer Cell. 2003;4:7-11.
38. Wakimoto H, Johnson PR, Knipe DM, Chiocca EA. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. 2003;10:983-990.
39. Peng KW, Holler PD, Orr BA, Kranz DM, Russell SJ. Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor. Gene Ther. 2004;11:1234-1239.
40. Bucheit AD, Kumar S, Grote DM, et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther. 2003;7:62-72.
41. Peng KW, Donovan KA, Schneider U, Cattaneo R, Lust JA, Russell SJ. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood. 2003;101:2557-2562.
42. Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol. 2001;75:2087-2096.
43. Schneider U, Bullough F, Vongpunsawad S, Russell SJ, Cattaneo R. Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol. 2000;74:9928-9936.
44. Obuchi M, Fernandez M, Barber GN. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol. 2003;77:8843-8856.